Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ASH18

- PMLiVE

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets

Biotheryx will receive up to $347m in potential milestone payments

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

The deal to develop a small-molecule inhibitor could be worth over $480m

- PMLiVE

FDA proposes improvements for oncology clinical trials supporting accelerated approval

The draft guidance discusses the advantage of randomised clinical trials over single-arm studies

- PMLiVE

Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

Medscape Oncology: Delivering Impact at ASH

You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...

Medscape Education Global

- PMLiVE

Ipsen to acquire worldwide rights to pre-clinical stage oncology programme

The company has an existing partnership with the Université de Montréal and IRICoR

- PMLiVE

BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

ICR discovery could lead to new series of cancer drugs

The team found new inhibitors that block the action of a cancer-driving protein

- PMLiVE

Kite and Arcellx close multiple myeloma collaboration agreement

This haematological malignancy is the third most common  in Europe and the US and is incurable for most patients

- PMLiVE

Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients

Kate Shaw, Innovative Trials' Founder & CEM, reflects on the exciting news for patients affected by cancer in the UK.

Innovative Trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links